Summary & Overview
HCPCS J2020: Injection, Linezolid 200 mg
HCPCS Level II code J2020 designates a 200 mg injection of linezolid, an antibiotic used for serious bacterial infections. Nationally, this code matters because it standardizes billing for parenteral linezolid across hospitals, outpatient infusion centers, and clinics, affecting reimbursement, formulary placement, and utilization management for a high-cost, targeted antibiotic.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding intent and clinical context, typical sites of service where J2020 is billed, and the payer landscape for coverage and claims processing. The publication summarizes common modifiers and administrative considerations, highlights benchmarks and utilization patterns where available, and outlines relevant policy updates that influence prior authorization, dosing units, and billing practices.
The content provides practical information for revenue cycle staff, clinicians, and policy stakeholders who manage infusion services and high-cost antimicrobials. Data not available in the input is noted where applicable; the focus remains on clarifying the code meaning, service context, and payer coverage implications at a national level.
Billing Code Overview
HCPCS Level II code J2020 represents Injection, linezolid, 200 mg. This billing code covers the administration or supply of a 200 mg dose of the antibiotic linezolid, typically used for treating certain serious bacterial infections.
Service Type: Parenteral antibiotic administration / Drug injection
Typical Site of Service: Inpatient hospital, outpatient infusion center, clinic, or other facility where intravenous or intramuscular medications are administered
Clinical & Coding Specifications
Clinical Context
A 68-year-old hospitalized patient with a complicated, drug-resistant Gram-positive infection (for example, hospital-acquired pneumonia or complicated skin and soft tissue infection) requires intravenous antibiotic therapy with linezolid. The inpatient infectious disease consult recommends parenteral administration of J2020 (injection, linezolid, 200 mg) when oral administration is contraindicated (e.g., impaired enteral absorption, aspiration risk, or inability to take oral medications) or while establishing therapeutic levels prior to oral step-down. The clinical workflow typically includes: admission evaluation, microbiology culture and sensitivity testing, infectious disease recommendation, verification of allergy history and renal/hepatic status, nursing preparation and administration of J2020 via IV push or infusion per facility protocol, monitoring for hematologic and neurologic adverse effects (complete blood count, platelet count, neuropathy symptoms), documentation of dose and lot number in medication administration record, and periodic reassessment for transition to oral therapy when appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure performed as usual; no modifier. | Use when no special circumstances apply to the administration of . |